Signup/Login
If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Signup/Login
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
Monitor
IPO today
Upcoming IPO
Priced IPO
Solaredge Technologies, Inc. (SEDG)
The Marygold Companies (MGLD)
Blue Water Vaccines (BWV)
Meihua International Medical Technologies (MHUA)
Smart for Life (SMFL)
Vivakor (VIVK)
TC BioPharm Holdings (TCBP)
Direct Digital Holdings, Llc (DRCT)
Modiv (MDV)
Sky Technologies (SKYX)
Modular Medical (MODD)
HeartCore Enterprises (HTCR)
Arcellx, Inc. (ACLX)
Silver Spike Investment Corp. (SSIC)
Maris-Tech Ltd. (MTEK)
Yoshitsu Co., Ltd. (TKLF)
Tpg Inc. (TPG)
Hillstream BioPharma (HILS)
Hour Loop (HOUR)
Vigil Neuroscience, Inc. (VIGL)
More companies

Miromatrix Medical, Inc (MIRO)

Sector - Healthcare

Price chart

N/A
Return from IPO

Company News

IPO Profile

About company

Company Logo
They are a life sciences company pioneering a novel technology for bioengineering fully transplantable human organs to help save and improve patients’ lives. Organ disease is a major public health issue. According to the American Transplant Foundation there are an estimated 114,000 people in the United States waiting for a lifesaving organ transplant, and on average 20 people die daily due to lack of available organs. They have developed a proprietary perfusion technology platform for bioengineering organs that they believe will efficiently scale to address the shortage of available human organs. Their initial development focus is on human livers and kidneys, and they have demonstrated the ability to bioengineer these organs with functional vasculature and important organ function in preclinical studies. In addition, they believe their technology platform will be able to develop other organs, including lungs, pancreas, and hearts. They have collaborations with the Mayo Clinic, Mount Sinai and the Texas Heart Institute, and their strategic investors include DaVita, Baxter and CareDx. They previously developed and commercialized two medical device products using their proprietary perfusion decellularization technology: Miromesh®, primarily utilized for hernia repair applications, and, Miroderm®, indicated for a variety of advanced wound care applications.
Industry
Biological Products (no Diagnostic Substances)
CEO CFO
Jeff Ross Brian Niebur
Employees Founded
36 2009

Contacts

Address: 10399 West 70th Street Eden Prairie, Mn 55344

Telephone: (952) 942-6000

Web page: http://www.miromatrix.com

IPO information

First Trade Date 6/24/2021
Status Priced
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range
-
Share prices ($)

Shares & Volumes

Shares Initial (MM) 4
Shares Revised (MM) 4.8
Expected offer amount (MM) $32
Realized offer amount(MM) $43.2

Financial Data (last reporting year)

Market Cap (MM) $142.16
Revenues (MM) $0.05
Net Income (Loss) (MM) $-10.3

Voting

What do you think will happen with the MIRO share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
The lead left underwriter: Craig Hallum

IPOs led by the firm .Pro
Profitability of conducted IPOs  ?  .Pro
1st day change  ?  .Pro
Change for the first 3 months  ?  .Pro
Underwriters
Craig Hallum
CO-Managers
-

Sector: Healthcare

Tweets about $MIRO

Tweets volume:

RT volume:

Timeframe:

Google Trends Stats